mail Whup! Whup!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi Diva.
Good to see you out & about.
Surfer Garrett McNamara May Have Conquered His 100-Foot Wave.
After chasing a record-setting wave for a dozen years, the veteran surfer says he may have ridden a 100-foot monster off the coast of Nazaré, Portugal. All that remains now is for Guinness to certify it as a world record.
http://www.thedailybeast.com/articles/2013/01/30/surfer-garrett-mcnamara-conquers-his-100-foot-wave.html
If you've been looking for new ideas, chances are you've been looking at stocks about to go public.
"So far, 2013 is turning out to be a real good year forIPOs," Cramer said. We've seen seven deals since the new year began, and at this point all of them have made you money."
4 of them, Bright Horizons , LipoScience, CyrusOne, and Norwegian Cruise Lines all popped by double digits on their first day of trade. The other 3 were master limited partnership IPOs that were not so hot in their first day of trading, but have since bounced back.
"That's a darned good track record, especially when you consider that we've got five more IPOs coming next week, including Zoetis, which is the spin-off of Pfizer's animal health division," said Cramer. Read More: Cramer - This IPO for the Dogs
(Having trouble viewing the video? Click here!)
However - not all IPOs are created equal.
"While January has been a fabulous month, they can't all be winners," Cramer reminded.
And one of the best ways to separate the best from the rest is too look back at 2012 and identify a theme. "That's a great way to figure out what's working and what isn't working," said Cramer.
If you can extrapolate a common idea from last year's winners, chances are you can apply that idea to determine which forthcoming IPOs may have the greatest chances at success.
------------------------------------------------------------------------
More from Cramer:
Cramer's Game Plan: 12 Stocks to Watch
Are Pullbacks Buying Opportunities
Cramer: This Semiconductor Stock Likely Bottomed
------------------------------------------------------------------------
Following are some of 2012's best performing IPOs.
VipShop Holdings - a Chinese social media IPO. "They're a a leading player in China's nascent flash sales market," Cramer explained.
Proto Labs (PRLB) - a company that rapidly manufacturers custom parts for prototyping. "Their technology is allowing them to take share for the traditional rapid injection molding businesses," Cramer said.
HomeStreet (HMST) - a full-service community bank that operates in the Pacific Northwest. "They have a highly profitable mortgage business. Remember the housing resurgence and the rise of the regional banks are two of my top ten favorite themes for 2013," Cramer said.
Guidewire (GWRE) - a tech company that provides software systems to the property and casualty insurance business. "It's a niche software company with rapid growth, defensible barriers to entry, and highly visible earnings streams," said Cramer
Intercept Pharma - an orphan drug developer. "Intercept's lead drug had very strong data and a large market opportunity. It's a company with growth that's protected and predictable," said Cramer.
Nationstar Mortgage Holdings (NSM) - the largest specialty mortgage servicer in the country. "Nationstar has been aggressively taking share in the ten trillion dollar mortgage servicing market," Cramer said.
Eloqua - a service company that's a leader in the revenue performance management space. "Eloqua provides companies with a platform that helps them figure out the value of their marketing initiatives; that's a big challenge for many businesses," said Cramer
WageWorks (WAGE) - a provider of on demand employee spending account benefits programs. "Just like companies can outsource your payroll to an ADP or a Paychex, companies can outsource the management of their flex spending accounts to WageWorks," said Cramer.
What's the one thing that all these winning IPO's have in common?
"Simple. One word. Growth," said Cramer.
"Last year, the IPOs with real, sustainable, unquestionable growth were the best performers, and this is a dynamic that should continue in 2013. I don't expect the market's appetite for growth to be easily sated."
Call Cramer: 1-800-743-CNBC
Questions for Cramer? madmoney@cnbc.com
Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com
I still have no sell at .0002
averaged at $0.000133
Doctor develops special glasses for migraine.
Doctor develops special glasses for migraine.
BTHE. Boston Therapeutics Announces Clinical Study Final Results Indicate That SUGARDOWN(R) Reduced the Post-Meal Elevation of Blood Glucose by up to 61% in Healthy Volunteers
No Severe Adverse Effects Observed
http://finance.yahoo.com/news/boston-therapeutics-announces-clinical-study-123000098.html
BTHE. Boston Therapeutics Announces Clinical Study Final Results Indicate That SUGARDOWN(R) Reduced the Post-Meal Elevation of Blood Glucose by up to 61% in Healthy Volunteers
No Severe Adverse Effects Observed
http://finance.yahoo.com/news/boston-therapeutics-announces-clinical-study-123000098.html
Patients' Own Skin Cells Are Transformed Into Heart Cells to Create "Disease in a Dish"
http://finance.yahoo.com/news/patients-own-skin-cells-transformed-181305682.html
Researchers at Sanford-Burnham Medical Research Institute and Johns Hopkins University Use Skin Cells From Patients With an Inherited Heart Condition to Recreate the Adult-Onset Disease in a Laboratory Dish -- Producing the First Maturation-Based Disease Model for Testing New Therapies
GlobeNewswirePress Release: Sanford-Burnham Medical Research Institute – 1 hour 33 minutes ago
LA JOLLA, Calif., Jan. 27, 2013 (GLOBE NEWSWIRE) -- Most patients with an inherited heart condition known as arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) don't know they have a problem until they're in their early 20s. The lack of symptoms at younger ages makes it very difficult for researchers to study how ARVD/C evolves or to develop treatments. A new stem cell-based technology created by 2012 Nobel Prize winner Shinya Yamanaka, M.D., Ph.D., helps solve this problem. With this technology, researchers can generate heart muscle cells from a patient's own skin cells. However, these newly made heart cells are mostly immature. That raises questions about whether or not they can be used to mimic a disease that occurs in adulthood. In a paper published January 27 in Nature, researchers at Sanford-Burnham Medical Research Institute and Johns Hopkins University unveil the first maturation-based "disease in a dish" model for ARVD/C. The model was created using Yamanaka's technology and a new method to mimic maturity by making the cells' metabolism more like that in adult hearts. For that reason, this model is likely more relevant to human ARVD/C than other models and therefore better suited for studying the disease and testing new treatments.
"It's tough to demonstrate that a disease-in-a-dish model is clinically relevant for an adult-onset disease. But we made a key finding here--we can recapitulate the defects in this disease only when we induce adult-like metabolism. This is an important breakthrough considering that ARVD/C symptoms usually don't arise until young adulthood. Yet the stem cells we're working with are embryonic in nature," said Huei-Sheng Vincent Chen, M.D., Ph.D., associate professor at Sanford-Burnham and senior author of the study.
To establish this model, Chen teamed up with expert ARVD/C cardiologists Daniel Judge, M.D., Joseph Marine, M.D., and Hugh Calkins, M.D., at Johns Hopkins University. Johns Hopkins is home to one of the largest ARVD/C patient registries in the world.
"There is currently no treatment to prevent progression of ARVD/C, a rare disorder that preferentially affects athletes. With this new model, we hope we are now on a path to develop better therapies for this life-threatening disease," said Judge, associate professor and medical director of the Center for Inherited Heart Disease at the Johns Hopkins University School of Medicine.
Disease in a dish
To recreate a person's own unique ARVD/C in the lab, the team first obtained skin samples from ARVD/C patients with certain mutations believed to be involved in the disease. Next they performed Yamanaka's technique: adding a few molecules that dial back the developmental clock on these adult skin cells, producing embryonic-like induced pluripotent stem cells (iPSCs). The researchers then coaxed the iPSCs into producing an unlimited supply of patient-specific heart muscle cells. These heart cells were largely embryonic in nature, but carried along the original patient's genetic mutations.
However, for nearly a year, no matter what they tried, the team couldn't get their ARVD/C heart muscle cells to show any signs of the disease. Without actual signs of adult-onset ARVD/C, these young, patient-specific heart muscle cells were no use for studying the disease or testing new therapeutic drugs.
Speeding up time
Eventually, the team experienced the big "aha!" moment they'd been looking for. They discovered that metabolic maturity is the key to inducing signs of ARVD/C, an adult disease, in their embryonic-like cells. Human fetal heart muscle cells use glucose (sugar) as their primary source of energy. In contrast, adult heart muscle cells prefer using fat for energy production. So Chen's team applied several cocktails to trigger this shift to adult metabolism in their model.
After more trial and error, they discovered that metabolic malfunction is at the core of ARVD/C disease. Moreover, Chen's team tracked down the final piece of puzzle to make patient-specific heart muscle cells behave like sick ARVD/C hearts: the abnormal over-activation of a protein called PPARg. Scientists previously attributed ARVD/C to a problem in weakened connections between heart muscle cells, which occur only in half of the ARVD/C patients. With the newly established model, they not only replicated this adult-onset disease in a dish, but also presented new potential drug targets for treating ARVD/C.
What's next?
Chen's team was recently awarded a new grant from the California Institute for Regenerative Medicine to create additional iPSC-based ARVD/C models. With more ARVD/C models, they will determine whether or not all (or at least most) patients develop the disease via the same metabolic defects discovered in this current study.
Together with the Johns Hopkins team, Chen also hopes to conduct preclinical studies to find a new therapy for this deadly heart condition.
This research was funded by the California Institute of Regenerative Medicine (grants RS1-00171-1, RB2-01512, and RB4-06276) and the U.S. National Institutes of Health (National Heart, Lung, and Blood Institute grant RO1HL105194). The study was co-authored by Changsung Kim, Sanford-Burnham; Jianyan Wen, Sanford-Burnham and China-Japan Friendship Hospital; Johnson Wong, Sanford-Burnham; Shirong Wang, Sanford-Burnham; Cheng Wang, Sanford-Burnham; Sean Spiering, Sanford-Burnham; Natalia G. Kan, Sanford-Burnham; Sonia Forcales, Sanford-Burnham; Pier Lorenzo Puri, Sanford-Burnham; Teresa C. Leone, Sanford-Burnham; Joseph E. Marine, Johns Hopkins University; Hugh Calkins, Johns Hopkins University; Daniel P. Kelly, Sanford-Burnham; Daniel P. Judge, Johns Hopkins University; and Huei-Sheng Vincent Chen, Sanford-Burnham and University of California, San Diego.
Heather Buschman, Ph.D.
Sanford-Burnham Medical Research Institute
hbuschman@sanfordburnham.org
(858) 610-3808
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. The Institute consistently ranks among the top five organizations worldwide for its scientific impact in the fields of biology and biochemistry (defined by citations per publication) and currently ranks third in the nation in NIH funding among all laboratory-based research institutes. Sanford-Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies. Sanford-Burnham is a U.S.-based, nonprofit public benefit corporation, with operations in San Diego (La Jolla), California and Orlando (Lake Nona), Florida. For more information, news, and events, please visit us at sanfordburnham.org.
Autoimmune Disorder: The Immune System's Dysfunction
http://www.empowher.com/wellness/content/autoimmune-disorder-immune-systems-dysfunction?page=0,0
Have you ever taken time to consider how lucky you are to have a properly functioning immune system? When it works we probably don’t even think about it.
For people who have disorders of the immune system it can be frustrating and stressful. The process of evaluating non-specific symptoms combined with intermittent, vague discomforts can sometimes last for years. For some, there is no specific diagnosis.
Every day that you are healthy is another day your immune system has successfully completed its job.
The job of our immune system is to protect us from disease and infection. When it is functioning correctly it helps our healthy cells by conducting surveillance for harmful organisms and destructive cells in our body.
This Article
Improved My Health
Changed My Life
Saved My Life
A healthy immune system is able to tell the difference between the healthy cells of the body and cells that cause harm to the body, usually viruses, bacteria or cancer cells.
When the immune system is not operating correctly, it can create havoc in the body that is far worse than any acute infection.
When it is not operating correctly the immune system is not able to distinguish between it’s cells and foreign cells and it attacks the healthy cells.
This general situation is called an autoimmune disorder. Autoimmune disorders occur when the immune system attacks the healthy cells of the body, creating disease processes in the body.
Autoimmune diseases are far more prevalent in women than in men. There is a genetic component which puts African-American, Hispanic-American, and Native-American women at higher risk for certain autoimmune diseases than women from other cultures.
They have currently identified over 80 different autoimmune diseases. Examples of autoimmune diseases are multiple sclerosis, rheumatoid arthritis, Hashimoto's thyroiditis, pernicious anemia, Addison's disease, systemic lupus erythematosus (SLE), Sjogren syndrome, lupus erythematosus, Grave's disease and celiac disease.
Diagnosing these diseases can be difficult because the symptoms may start out as simple as being tired, feeling muscle aches and low fever.
It is important to start to keep track of these symptoms and share them with your doctor.
If they brush off the symptoms but you know something is wrong do not be afraid to get another opinion. Getting the right diagnosis is the first step to finding the best treatment.
Trust yourself when you know something is not right and talk to your doctor about getting tested for autoimmune conditions, even if you have to see a specialist.
8 Child-Friendly Vitamins and Nutrients To Boost Their Immune Systems
http://health.yahoo.net/articles/children/8-child-friendly-vitamins-and-nutrients-boost-their-immune-systems
Holland Michigan ice sculpture competition.
Most Shorted Tickers:
Sort By
Volume
UYMG
NSAV
UNGS
CERP
CPSZ
HRDN
MWWC
FARE
HPCS
SBRH
VNDB
COWI
BMSN
FROG
ATTD
Saturday in The Park. Chicago 1973.
WSJournal Market Data.
http://online.wsj.com/img/mdc_logo.gif
Everybody come visit me at my new home.
Coffee Shoppe
(in my profile).
10 ways to trade penny stocks.
The allure of penny stocks is simple: They don’t cost much money and promise big profits. But trading penny stocks is also a good way to lose money.
Sure, it’s possible to profit when you understand the game, but the odds are against you when you don’t. And worse: manipulators and scammers often run the penny-stock game.
For investors who can’t afford shares of Google or Apple, the potential gains from trades like this are too good to pass up. So penny-stock trading thrives. With a relatively small investment you can make a nice return if — and this is a big if — the trade works out. For example, say you buy 10,000 shares of a $.30 stock for $3,000. If the stock reaches $1, you’ve made $7,000, doubling your money. Read more: 5 strategies if you have less than $3,000 to invest. )
Dollars and sense
Penny stock promoters make sure to attach a disclaimer to their email, Twitter, or Facebook page, and take advantage of this language to embellish and deceive. Read more: Stock touts prey on investors' inflation fears.
Penny stocks and their promoters also tend to stay one step ahead of securities regulators, though just last month the Securities and Exchange Commission charged a Florida-based firm, First Resource Group LLC, with penny-stock manipulation. Read more: Simple rule: Don't buy a penny stock.
Even with these clear dangers, some people insist on trading the pennies. So, if you find yourself on the receiving end of a telephone call from a penny-stock promoter, or you spot an advertisement that promises dollars from your pennies — and you still decide that maybe penny stocks aren’t wooden nickels, just remember these 10 rules:
1. Ignore penny-stock success stories
Timothy Sykes, a penny-stock expert who trades both long and short, says you must not believe the penny-stock stories that are touted in emails and on social media websites.
“You have to say no,” Sykes said. “You can’t invest in penny stocks as if they were lotto tickets, but unfortunately that’s what most people do, and they lose again and again. Think of penny stocks as inmates in a prison that you can’t trust.”
Instead, Sykes says, focus on the profitable penny stocks with solid earnings growth and which are making 52-week highs.
2. Disregard tips and read the disclaimers
Penny stocks are sold more than bought — mostly via tips that come your way in emails and newsletters.
“The free penny-stock newsletters are not giving you tips out of the goodness of their heart,” Sykes said. “If you read the disclaimers at the bottom of the newsletters, they are getting paid to pitch a stock because their investors want exposure for the company. There is nothing wrong with wanting exposure, but almost all penny newsletters make false promises about their crappy companies.”
Sykes says there is a difference between stocks making a 52-week high based on an earnings breakout and stocks making a 52-week high because three newsletters picked it. Reading the disclaimers at the bottom of the email or newsletter, which the SEC requires them to do, will usually reveal a conflict of interest.
“Most newsletters don’t tell you the truth,” Sykes said. “They are being compensated to pump up the stock, and they rarely tell you when to sell. Often it’s far too late.”
3. Sell quickly
One allure of penny stocks is you can make 20% or 30% in a few days. If you make that kind of return with a penny stock, sell quickly.
Unfortunately, many traders get greedy, aiming for a 1,000% return. Considering that the penny stock you’re in might be getting pumped up, take any profits and move on.
4. Never listen to company management
In the murky penny-stock world, don’t believe what you hear from companies.
“You can’t trust anyone,” Sykes said. “The companies are trying to get their stock up so they can raise money and stay in business. There is no reliable business model or accurate data, so most penny stocks are scams that are created to enrich insiders.”
Sykes says large rings of the same people run promotions using different press releases and companies, including the reappearance of a notorious stock manipulator who was first convicted for an email pump-and-dump scheme when he was in high school.
5. Don’t sell short
Although shorting pumped-up penny stocks may seem attractive, don’t do it.
Penny stocks are too volatile, and if you’re on the wrong side of the trade, you could easily lose 50% or more on a short squeeze. Another problem is that it’s difficult to find shares of penny stock to short, especially those that made huge moves based on hype and newsletter tips. Leave shorting penny stocks to the pros.
6. Focus only on penny stocks with high volume
Stick with stocks that trade at least 100,000 shares a day. If you trade stocks with low volume, it could be difficult to get out of your position.
“You must be aware of the number of shares traded and the dollar volume,” Sykes said. He also suggests that you trade penny stocks that are priced at more than 50 cents a share. “Stocks that are trading less than 100,000 shares a day and are under 50 cents a share are not liquid enough to be in play,” he added.
7. Use mental stops
Because the bid-ask spreads on many penny stocks can be high, as much as 10%, hard stop-losses can actually cause you to lose money. p>
Although it takes more concentration, use mental stops. “I focus more on risk-reward than stops,” Sykes said. “If I want to make a dollar a share on a three-dollar stock, I will cut my losses at 20 cents so I have a 5:1 risk reward. I aim for 3:1 or 4:1, but not 1:1 or 2:1. If I think a dollar stock has only 50-cents upside (2:1), my mental stop loss will be at 10 cents because the risk-reward is better.”
8. Buy the best of the bunch
Sykes looks to buy penny stocks that have had an earnings breakout.
“I love buying penny stocks when they have good earnings, or when they are breaking out to 52-week highs on volume that is at least a quarter million shares a day,” he said. “They are easy to find if you look.”
The challenge is to find stocks that make 52-week highs that aren’t due to a pump-and-dump scheme. Examples of penny stocks that have fit Syke’s criteria in the past include Tangoe, Magal Security Systems, and Staar Surgical Co.
9. Don’t trade large positions
“You really need to be careful with position sizing,” Sykes said. “I learned the hard way not to trade big. My rule now is not to trade more than 10% of the stock’s daily volume.”
In addition, he said, limit your share size so you can get out of the stock faster.
10. Don’t fall in love with a stock
Every penny stock company wants you think it has an exciting story that will revolutionize the world. If you enter the penny stock arena, be cynical, do your own research, and diversify, even if a friends or family member is touting a stock.
Penny stocks have earned their bad reputation, so beware.
Jim Cramer - His - homebuilders, led by Pulte ( PHM _ ) , Lennar ( LEN _ ) and Toll Brothers ( TOL _ ) . We had the housing-related retailers -- Home Depot ( HD _ ) , Williams-Sonoma ( WSM _ ) , Pier 1 ( PIR _ ) and Lowe's ( LOW _ ) . We had the building-products companies -- Louisiana-Pacific ( LPX _ ) , Weyerhaeuser ( WY _ ) , Rayonier ( RYN _ ) , Plum Creek Timber ( PCL _ ) , USG ( USG _ ) and Owens Corning ( OC _ ) . We had the suppliers, like Whirlpool ( WHR _ ) , Newell Rubbermaid ( NWL _ ) , Masco ( MAS _ ) and Mohawk ( MHK _ ) . All of these will also be helped by the eventual rebuild that must happen in the aftermath of Hurricane Sandy -- which, while not as big as that following Katrina, will help spur the second quarter's gross domestic product growth.
CRMB. holding. $3.07 Stock Maven buy.
http://www.insidestocks.com/texpert.asp?sym=crmb&code=BMAVN
FMAR. At resistance breakout. $1.00 Stock Maven buy.
http://www.insidestocks.com/texpert.asp?sym=fmar&code=BMAVN
Got any videos without clicking on ads?
HI CH. I can't reply with a PM now.
I really like CERP products.
The chart needs a bottom!
I am at my new Coffee Shoppe (my profile).
ACGX dd-sheet reposted.
From StocksDiva. APDN to Provide Unique DNA Mark to Forward Components, Inc. for DNA-Marking of Microcircuits
http://investorshub.advfn.com/StocksDiva-Bio-Bin-16112/
Symbol Price Change
APDN 0.213
STONY BROOK, NY--(Marketwire - Jan 17, 2013) - Applied DNA Sciences, Inc. ( OTCBB : APDN ), (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced today that Forward Components, Inc. (Forward Components Engineering, or FCE), based in Foothill Ranch, CA, has requested a unique DNA mark from APDN for DNA-marking for FSC 5962 microcircuits in accordance with the mandate issued by the U.S. Defense Logistics Agency (DLA). The mandate requires use of APDN's SigNature® DNA marking on a certain class of microcircuits, FSC 5962.
FCE will be required to undergo an in-house inspection and training prior to receiving the unique DNA mark to determine if they will qualify to mark in-house or will require third party marking initially. Quality control testing is an ongoing requirement to ensure that all parts continue to be marked correctly for as long as FCE marks parts with a unique APDN DNA marker.
FCE is an authorized distributor and assembly/test facility for the military and aerospace hi-rel industries. The company will apply their SigNature DNA Provenance mark to electronic parts which have traceable documentation as well as parts known as non-trace legacy components. The latter, which comprise only about 5% of the business of FCE, are parts which lack traceability documentation, but which are subject to rigorous test and inspection methods at the FCE facility. These parts, sometimes called "obsolete," can be vital to many military applications due to the long life of much military equipment.
FCE owner and President Scott Wilkosz stated, "Forward Components is pleased to offer DNA-marking on their 5962 components as a value-added service. This technology fits well with our core philosophy of strong quality control and 'best-practice' solutions for our hi-rel customers. Outside of DLA, we invite other customers to request DNA-marked parts from us, knowing that they will essentially be procuring an added layer of forensic protection for their supply-chain."
The Provenance mark to be used by FCE is one of two forms of APDN's SigNature DNA mark: the SigNature Authenticity mark, which is intended to authenticate original products manufactured by OCMs, and the SigNature Provenance mark for distributed products that are marked after manufacture.
The majority of materials FCE distributes are fully traceable; however, when a customer, such as DLA, requests an obsolete legacy component that does not have traceability, the on-staff engineering team at FCE screens these parts using test and inspection methods outlined in the recently approved SAE standard AS6081. Only after these parts are subjected to the test and inspection methods, and are shown to meet AS6081 criteria, will FCE then apply their SigNature DNA Provenance mark.
Bob MacDowell, Senior Account Representative at APDN, commented: "This DNA Provenance Mark will be unique to FCE, and is a testimony to their commitment to quality and best practices for the hi-rel component business."
Dr. James A. Hayward, President and CEO of Applied DNA Sciences, stated: "We are pleased to welcome FCE as another partner in the effort to protect the military supply chain and bring additional value to their businesses. As the DLA-mandated program for DNA marking and authentication grows and develops, we continue to widen the options for electronics companies wishing to join the program and gain its benefits."
About Forward Components Engineering
FCE is an authorized distributor and assembly/test facility for the military and aerospace hi-rel industries. With an on-site engineering staff and a technical sales team, Forward is able to utilize first-class quality systems and in-depth product to offer customers solution-based programs, including distribution and logistics services, cable and harness assembly, through-hole board assembly, and military compliant/RFID packaging. FCE offers extensive test capabilities for AC, DC, and functional testing for a wide array of devices in support of current and legacy programs. Parts inspections are compliant with IDEA-STD-1010 and the appropriate MIL-STD-883 standards. FCE is an ISO 9001:2008 certified company and has successfully contracted with various branches of the Armed Forces and Primes in support of the MV22, Blue Force Tracker, F/A-18 and many other vital programs critical to the success of the American Warfighter. For more information please contact us at info@forwardcomponents.com.
About Applied DNA Sciences
APDN is a provider of botanical-DNA based security and authentication solutions that can help protect products, brands and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA and smartDNA™, our principal anti-counterfeiting and product authentication solutions that essentially cannot be copied, provide a forensic chain of evidence and can be used to prosecute perpetrators.
The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 20, 2012 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.
Contact:
MEDIA CONTACT:
Mitchell Miller
646-543-3373
fax: 631-444-8848
INVESTOR CONTACT:
Debbie Bailey
631-444-8090
fax: 631-444-8848
FCMN
Email Contact
PROGRAM CONTACT:
Janice Meraglia
631-444-6293
Web site: http://www.adnas.com
Twitter: @APDN, @APDNInvestor
APDN reposted. Thanks.
Thanks jhnvtjll. EPGL.
Thanks Salty. I used to listen to that and a few other Bob Dylan
albums a lot.
Well I Ain't Gonna Work On Maggie's Farm No More.
WSJournal. Market Data.
http://online.wsj.com/mdc/page/marketsdata.html?mod=WSJ_topnav_marketdata_main
Nasdaq after hours.
http://www.nasdaq.com/extended-trading/afterhours-mostactive.aspx
Gran Turismo 5 - 2014 Corvette Stingray Trailer Video/Trailer.
Have a great weekend everybody.
Hi CH.
I hang out at my new home.
Link on my coffee ........ profile.
Nasdaq premarket.
http://www.nasdaq.com/extended-trading/premarket-mostactive.aspx
ALL time highs. 174.
http://www.barchart.com/stocks/athigh.php?_dtp1=0